Netflix and pill: is there a role for volume-delinked subscription-style payments beyond antimicrobials?'

G Hampson, L Steuten - Expert review of pharmacoeconomics & …, 2024 - Taylor & Francis
Volume-delinked subscription-style payments, also known as 'Netflix-models,'are a novel
pricing and reimbursement model in pharmaceutical markets. Under this type of agreement …

Guidance for demonstrating the societal value of new antibiotics

S Simoens, I Spriet - Frontiers in Pharmacology, 2021 - frontiersin.org
Given that antibiotic use is associated with externalities, standard economic evaluation
which considers costs and health gains accruing to patients under-values antibiotics …

[HTML][HTML] Antimicrobial resistance: is health technology assessment part of the solution or part of the problem?

AR Colson, A Morton, C Årdal, K Chalkidou, SC Davies… - Value in Health, 2021 - Elsevier
Antimicrobial resistance is a serious challenge to the success and sustainability of our
healthcare systems. There has been increasing policy attention given to antimicrobial …

The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study

C Kållberg, L Mathiesen, U Gopinathan… - … Policy and Practice, 2023 - Taylor & Francis
Background Few antibiotics have entered the market in recent years despite the need for
new treatment options. Some of the challenges of bringing new antibiotics to market are …

[HTML][HTML] Value assessment of antimicrobials using the STEDI framework–How steady is the outcome?

S Brassel, A Al Taie, L Steuten - Health Policy, 2023 - Elsevier
Antimicrobial resistance (AMR) is one of the major threats to global population health, and
the antimicrobial market requires substantial reimbursement reform and/or significant …

How should the value attributes of novel antibiotics be considered in reimbursement decision making?

A Morton, A Colson, A Leporowski… - MDM Policy & …, 2019 - journals.sagepub.com
Antibiotics have revolutionized the treatment of bacterial infections. However, it is widely
held that there is underinvestment in antibiotics research and development relative to the …

[HTML][HTML] Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model

B Woods, L Schmitt, D Jankovic… - Health Technology …, 2024 - pmc.ncbi.nlm.nih.gov
BACKGROUND To limit the use of antimicrobials without disincentivising the development of
novel antimicrobials, there is interest in establishing innovative models that fund …

Conducting value for money analyses for non-randomised interventional studies including service evaluations: an educational review with recommendations

M Franklin, J Lomas, G Richardson - Pharmacoeconomics, 2020 - Springer
This article provides an educational review covering the consideration of conducting 'value
for money'analyses as part of non-randomised study designs including service evaluations …

Cost effectiveness of ceftolozane/tazobactam compared with meropenem for the treatment of patients with ventilated hospital-acquired bacterial pneumonia and …

J Naik, L Puzniak, S Critchlow, D Elsea… - Infectious diseases and …, 2021 - Springer
Introduction The clinical efficacy and safety of ceftolozane/tazobactam for the treatment of
ventilated hospital-acquired bacterial pneumonia (vHABP) and ventilator-associated …

[HTML][HTML] An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population

MS Chan, R Holloway, R King, R Polya… - Journal of Health …, 2023 - ncbi.nlm.nih.gov
Background: Traditional health economic evaluations of antimicrobials currently
underestimate their value to wider society. They can be supplemented by additional value …